Skin cancer

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Retrieved on: 
Friday, January 5, 2024

Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised

Confusion about insurance coverage for cervical cancer screenings contributes to missed screening

Retrieved on: 
Wednesday, January 3, 2024

The 2023 survey shows 41% of American women are not up to date on cervical cancer screenings.2 This indicates an urgent need to discuss the cost of cervical cancer screening, as many people may be unaware cervical cancer screenings are covered through Medicaid and most private insurance plans.

Key Points: 
  • The 2023 survey shows 41% of American women are not up to date on cervical cancer screenings.2 This indicates an urgent need to discuss the cost of cervical cancer screening, as many people may be unaware cervical cancer screenings are covered through Medicaid and most private insurance plans.
  • That means, under current law, if you have health insurance and you have a cervix, your cervical cancer screenings are covered.
  • The elimination of cervical cancer will be severely hindered without proper education across all populations about screening, insurance coverage and HPV vaccination.
  • 2The cancer screenings studied in this survey were for breast cancer, cervical cancer, colorectal cancer, oral cancer, lung cancer, prostate cancer, skin cancer and testicular cancer.

U.S. Dermatology Partners Expands Weatherford Office, adding 2,921 square feet and seven Mohs Surgery Rooms

Retrieved on: 
Wednesday, January 3, 2024

WEATHERFORD, Texas, Jan. 3, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the expansion of its Weatherford, Texas, location. The expanded office is located at 1709 Martin Drive in Weatherford, Texas, and will open on January 2, 2024. The 9,095 square foot expanded location features 2,921 square feet of additional space, a larger lobby and front desk reception area, seven new Mohs surgery rooms, as well as a dedicated waiting area for Mohs surgery patients, additional space for general dermatology patients, and upgraded rooms for aesthetic treatments. The new space will provide a more comfortable environment and experience for patients and more room for our growing general dermatology team. Patients can expect the same comprehensive care they have become accustomed to from the same great team they already trust. Available services include annual skin examinations, medical dermatology for the treatment of chronic skin conditions, diagnosis and treatment options for skin cancer, and medical-grade skin care products.

Key Points: 
  • WEATHERFORD, Texas, Jan. 3, 2024 /PRNewswire-PRWeb/ -- U.S. Dermatology Partners is pleased to announce the expansion of its Weatherford, Texas , location.
  • The 9,095 square foot expanded location features 2,921 square feet of additional space, a larger lobby and front desk reception area, seven new Mohs surgery rooms, as well as a dedicated waiting area for Mohs surgery patients, additional space for general dermatology patients, and upgraded rooms for aesthetic treatments.
  • The new space will provide a more comfortable environment and experience for patients and more room for our growing general dermatology team.
  • To schedule an appointment at U.S. Dermatology Partners Weatherford, please contact the office at (817) 594-5880 or click here to request an appointment online.

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Thinking of a(nother) tattoo this summer? What you need to know about sunburn, sweating and fading

Retrieved on: 
Saturday, December 30, 2023

More of us have tattoos than ever before. About 25% of Australians are inked. A tattoo can be a large investment in time, money and pain. So how do you take care of your tattooed skin? Here’s what you need to know about sunburn, sweating and fading.

Key Points: 


More of us have tattoos than ever before. About 25% of Australians are inked. A tattoo can be a large investment in time, money and pain. So how do you take care of your tattooed skin? Here’s what you need to know about sunburn, sweating and fading.

Read more:
Tattoos have a long history going back to the ancient world – and also to colonialism

What’s a tattoo, dermatologically speaking?


Tattoo inks are deposited in the layer of skin called the dermis. This layer contains sweat and oil glands, a blood supply, immune cells, collagen to support the skin’s structures, and fibroblasts, which produce collagen.
Fibroblasts take up the ink particles, as do immune cells in the dermal tissue known as macrophages. The ink particles also stick inside bundles of collagen. Between these three mechanisms, the dermis holds tattoo inks so well they can be seen even on the 5,300-year-old ice mummy Ötzi.

Read more:
What Ötzi the prehistoric iceman can teach us about the use of tattoos in ceremonial healing or religious rites

Can I get a tattoo if I’m sunburnt?

  • During sunburn, your skin calls in extra immune cells and fluid to kill off and break down cells that have too much UV damage.
  • This inflammation can affect the tattoo ink deposits.

How soon after my new tattoo can I go into the sun?


There’s not much research on how soon you can expose your new tattoo to the sun. However, most tattooists advise you to avoid sun exposure while the tattoo heals, generally about three weeks. This seems sensible, as your fresh tattoo is a type of wound.

  • There is an influx of immune cells to deal with the damage, much like a sunburn.
  • So, in one way, you should treat your new tattoo like sunburn and avoid sun exposure while it heals.
  • But you shouldn’t use sunscreen on the tattoo in that time.

What happens if my tattoo gets sunburnt?

  • There’s usually swelling, itching or stinging on the tattoo site that can start immediately or develop over the course of a day.
  • There is also a small amount of evidence that sunburn on a tattoo temporarily suppresses the skin’s immune system, allowing an infection to become established.

Do tattoos increase my risk of skin cancer?

  • However, there’s no evidence skin cancers are more likely in tattooed skin.
  • Tattoos make newly-developed skin cancers more difficult to detect.
  • Red tattoos seem to be more prone to large but benign (non-cancerous) skin tumours called keratoacanthomas.
  • However, they can be difficult to distinguish from squamous cell carcinomas (a type of skin cancer).

Can sunlight fade my tattoo?

  • As tattoos age, they can fade a bit as some of the loose ink particles filter deeper into the dermis.
  • Sun exposure can also degrade ink particles.
  • After all, most people don’t want to fade their tattoos for science.

Does tattooed skin sweat differently to un-inked skin?

  • If you’ve got a full sleeve or your whole back is your canvas, that’s a significant amount of skin.
  • Since tattooing punctures the skin repeatedly, sweat glands in the dermis may be damaged.
  • However, when other researchers looked at sweating induced by exercise there was no effect in the volume of sweat between tattooed and un-tattooed skin.

Longer-term risks


When performed under the clean conditions of a licenced tattoo parlour, tattooing is relatively safe. But long term, some people develop allergic reactions to certain colours due to the different compounds in each, most commonly red dyes. This can cause lumps, scales, scarring or other visible changes. So, what’s the most common long-term side effect of tattoos? Tattoo regret and wanting to have them removed.
Katie Lee receives funding from the National Health and Medical Research Council. Erin McMeniman does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in DermTech, Inc. of Class Action Lawsuit And Upcoming Deadline – DMTK

Retrieved on: 
Thursday, December 14, 2023

Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the “Exchange Act”).

Key Points: 
  • Plaintiff pursues claims against the Defendants under the Securities Exchange Act of 1934 (the “Exchange Act”).
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Pomerantz Law Firm Announces the Filing of a Class Action Against DermTech, Inc. and Certain Officers – DMTK

Retrieved on: 
Wednesday, December 6, 2023

NEW YORK, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) and certain of its officers.

Key Points: 
  • NEW YORK, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against DermTech, Inc. (“DermTech” or the “Company”) (NASDAQ: DMTK) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered billions of dollars in damages awards on behalf of class members.

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

Retrieved on: 
Tuesday, December 5, 2023

The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.

Key Points: 
  • The CERPASS study was conducted under a Master Clinical Trial Collaboration and Supply Agreement with Regeneron Pharmaceuticals.
  • The ORR was comparable between the two study groups (52.5% for RP1 plus cemiplimab vs. 51.4% for cemiplimab alone, p=0.692).
  • The registration directed anti-PD1 failed melanoma cohort from the IGNYTE clinical trial includes 140 patients and completed enrollment earlier this year.
  • RP1 monotherapy was well tolerated, and the safety profile was similar to that observed in non-immunocompromised patients with advanced skin cancers.

Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study

Retrieved on: 
Tuesday, November 28, 2023

VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver based biopharmaceutical company with a focus on skin disease, is excited to announce that it is collaborating with Dr. Anna Mandinova from the Department of Dermatology at Massachusetts General Hospital in a skin cancer study.

Key Points: 
  • VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver based biopharmaceutical company with a focus on skin disease, is excited to announce that it is collaborating with Dr. Anna Mandinova from the Department of Dermatology at Massachusetts General Hospital in a skin cancer study.
  • Derm-Biome has developed a second-generation topical treatment for precancerous skin conditions (such as actinic keratosis) and non-melanoma skin cancers that is highly selective for cancer cells while being well-tolerated by normal skin.
  • Soaring skin cancer rates are reaching all-time highs in many parts of the world, and there are now more global deaths from non-melanoma skin cancers than melanoma itself.
  • Dr. Anna Mandinova, Associate Professor, Harvard Medical School, and Associate Director of the Massachusetts General Hospital Cutaneous Biology Research Center says: “My lab previously treated primary patient-derived squamous cell carcinoma cells and normal keratinocytes with a Derm-Biome compound.

Shiseido to Acquire Dr. Dennis Gross Skincare

Retrieved on: 
Friday, December 22, 2023

Shiseido Company, Limited (The Prime Market of the Tokyo Stock Exchange: 4911) (“Shiseido”, “Company”) today announced that Shiseido Americas Corporation (“Shiseido Americas”), a subsidiary of Shiseido, has signed a definitive agreement to acquire DDG Skincare Holdings LLC, the owner of Dr. Dennis Gross Skincare brand which offers dermatologist-led, science-based prestige skincare that has revolutionized the beauty industry by bringing high-level products to consumers everywhere.

Key Points: 
  • Shiseido Company, Limited (The Prime Market of the Tokyo Stock Exchange: 4911) (“Shiseido”, “Company”) today announced that Shiseido Americas Corporation (“Shiseido Americas”), a subsidiary of Shiseido, has signed a definitive agreement to acquire DDG Skincare Holdings LLC, the owner of Dr. Dennis Gross Skincare brand which offers dermatologist-led, science-based prestige skincare that has revolutionized the beauty industry by bringing high-level products to consumers everywhere.
  • With the addition of Dr. Dennis Gross Skincare, Shiseido seeks to accelerate and strengthen its core prestige skincare business which includes brands SHISEIDO and Clé de Peau Beauté.
  • Dr. Dennis Gross Skincare was launched in 2000 by former skin cancer researcher and practicing dermatologist, Dr. Dennis Gross, and his wife, Carrie Gross.
  • Gross, Co-Founder of Dr. Dennis Gross Skincare and Chief Science Officer and Carrie Gross, Co-Founder and Chief Executive Officer said, “We launched Dr. Dennis Gross Skincare in 2000 with the mission of making a difference in the lives of all people everywhere by helping them achieve healthier skin.